Drug metabolising enzyme polymorphisms in Middle- and Eastern-European Slavic populations

Drug Metabolism and Drug Interactions

Volumn 29, Issue 1, 2014, Pages 29-36

  Hubacek, Jaroslav A ^a  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

Drug metabolising enzymes; Drug transporters; Eastern Europe; Middle Europe; Polymorphisms; Slavic populations

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLIZING ENZYME; MULTIDRUG RESISTANCE PROTEIN 1;

CROATIA; CZECH REPUBLIC; DRUG METABOLISM; EASTERN EUROPE; ENZYME POLYMORPHISM; GENETIC VARIABILITY; POLAND; REVIEW; RUSSIAN FEDERATION; SERBIA;

CYTOCHROME P-450 ENZYME SYSTEM; EUROPE; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC;

EID: 84896756901     PISSN: 07925077     EISSN: None     Source Type: Journal    
DOI: 10.1515/dmdi-2013-0052     Document Type: Review

References (47)

1. Pereira NL, Weinshilboum RM. Cardiovascular pharmacogenomics and individualized drug therapy. Nat Rev Cardiol 2009;6: 632-8.
2. Sanford JC, Guo Y, Sadee W, Wang D. Regulatory polymorphisms in CYP2C19 affecting hepatic expression. Drug Metabol Drug Interact 2013;28: 23-30.
3. Meyer UA. Cytochrome P450 enzymes. Drug Metabol Drug Interact 2012;27: 1-2.
4. Raunio H, Rahnasto-Rilla M. CYP2A6: genetics, structure, regulation, and function. Drug Metabol Drug Interact 2012;27: 73-88.
5. Małek LA, Przyłuski J, Spiewak M, Kłopotowski M, Kostrzewa G, Kruk M, et al. Cytochrome P450 2C19 polymorphism, suboptimal reperfusion and all-cause mortality in patients with acute myocardial infarction. Cardiology 2010;117: 81-7.
6. Gawrońska-Szklarz B, Adamiak-Giera U, Wyska E, Kurzawski M, Gornik W, Kaldonska M, et al. CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers. Eur J Clin Pharmacol 2012;68: 1267-74.
7. Skretkowicz J, Barańska M, Kaczorowska A, Rychlik-Sych M. Genetic polymorphisms of CYP2D6 oxidation in patients with systemic lupus erythematosus. Arch Med Sci 2011;7: 864-9.
8. Gajecka M, Rydzanicz M, Jaskula-Sztul R, Kujawski M, Szyfter W, Szyfter K. CYP1A1, CYP2D6, CYP2E1, NAT2, GSTM1 and GSTT1 polymorphisms or their combinations are associated with the increased risk of the laryngeal squamous cell carcinoma. Mutat Res 2005;574: 112-23.
9. Cichoz-Lach H, Celiński K, Słomka M. Alcohol-metabolizing enzyme gene polymorphisms and alcohol chronic pancreatitis among Polish individuals. HPB (Oxford) 2008;10: 138-43.
10. Laczmanska I, Gil J, Karpinski P, Stembalska A, Kozlowska J, Busza H, et al. Influence of polymorphisms in xenobiotic-metabolizing genes and DNA-repair genes on diepoxybutane-induced SCE frequency. Environ Mol Mutagen 2006;47: 666-73.
11. Zochowska D, Wyzgał J, Paczek L. Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients. Ann Transplant 2012;17: 36-44.
12. Spiewak M, Małek ŁA, Kostrzewa G, Kisiel B, Serafin A, Filipiak KJ, et al. Influence of C3435T multidrug resistance gene-1 (MDR-1) polymorphism on platelet reactivity and prognosis in patients with acute coronary syndromes. Kardiol Pol 2009;67: 827-34.
13. Buzková H, Pechandová K, Danzig V, Vařeka T, Perlík F, Žák A, et al. Lipid-lowering effect of fluvastatin in relation to the cytochrome P450 2C9 variant alleles frequently distributed in the Czech population. Med Sci Monit 2012 2012;18:CR512-7.
14. Buzková H, Pechandová K, Slanař O, Perlík F. Frequency of single nukleotide polymorphisms of CYP2D6 in the Czech population. Cell Biochem Funct 2008;26: 76-81.
15. Slanar O, Drazd'áková M, Babiárová K, Pechandová K, Buzková H, Perlik F, et al. [Genotyping of CYP2D6 and CYP2C19]. Cas Lek Cesk 2007;146:708-11. (article in Czech).
16. Slanar O, Dupal P, Matouskova O, Vondrackova H, Pafko P, Perlik F. Tramadol efficacy in patients with postoperative pain in relation to CYP2D6 and MDR1 polymorphisms. Bratisl Lek Listy 2012;113: 152-5.
17. Pindurová E, Žourková A, Zrůstová J, Juřica J, Pavelka A. Alternative reliable method for cytochrome P450 2D6 poor metabolizers genotyping. Mol Biotechnol 2013;53: 29-40.
18. Pechandová K, Buzková H, Slanar O, Perlík F. Polymorphisms of the MDR1 gene in the Czech population. Folia Biol (Praha) 2006;52: 184-9.
19. Matouskova O, Slanar O, Adamkova J, Pafko P, Perlik F, Adamek S. Impact of MDR1 genetic polymorphisms on postoperative piritramide analgesia. Bratisl Lek Listy 2013;114: 133-5.
20. Bandur S, Petrasek J, Hribova P, Novotna E, Brabcova I, Viklicky O. Haplotypic structure of ABCB1/MDR1 gene modifies the risk of the acute allograft rejection in renal transplant recipients. Transplantation 2008;86: 1206-13.
21. Pechandova K, Buzkova H, Matouskova O, Perlik F, Slanar O. Genetic polymorphisms of CYP2C8 in the Czech Republic. Genet Test Mol Biomarkers 2012;16: 812-6.
22. Nakajima M, Fujiki Y, Noda K, Ohtsuka H, Ohkuni H, Kyo S, et al. Genetic polymorphisms of CYP2C8 in Japanese population. Drug Metab Dispos 2003;31: 687-90.
23. Cífková R, Skodová Z, Bruthans J, Adámková V, Jozífová M, Galovcová M, et al. Longitudinal trends in major cardiovascular risk factors in the Czech population between 1985 and 2007/8. Czech MONICA and Czech post-MONICA. Atherosclerosis 2010;211: 676-81.
24. Jurcikova L, Adamkova V, Lanska V, Suchanek P, Hubacek JA. Lack of association between variants within the AHSG, HRCT and NPY2R genes and anthropometrical parameters in Czech post MONICA study. Balk J Med Gen 2013;16: 63-8.
25. Djordjevic N, Carrillo JA, Gervasini G, Jankovic S, Aklillu E. In vivo evaluation of CYP2A6 and xanthine oxidase enzyme activities in the Serbian population. Eur J Clin Pharmacol 2010;66: 571-8.
26. Milojkovic M, Stojnev S, Jovanovic I, Ljubisavljevic S, Stefanovic V, Sunder-Plassman R. Frequency of the C1236T, G2677T/A and C3435T MDR1 gene polymorphisms in the Serbian population. Pharmacol Rep 2011;63: 808-14.
27. Brocic M, Supic G, Zeljic K, Jovic N, Kozomara R, Zagorac S, et al. Genetic polymorphisms of ADH1C and CYP2E1 and risk of oral squamous cell carcinoma. Otolaryngol Head Neck Surg 2011;145: 586-93.
28. Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, Brockmöller J, Frötschl R, Köpke K. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol 2003;59: 303-12.
29. Makeeva O, Stepanov V, Puzyrev V, Goldstein DB, Grossman I. Global pharmacogenetics: genetic substructure of Eurasian populations and its effect on variants of drug-metabolising enzymes. Pharmacogenomics 2008;9: 847-68.
30. Bozina N, Granić P, Lalić Z, Tramisak I, Lovrić M, Stavljenić- Rukavina A. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population. Croat Med J 2003;44: 425-8.
31. Mihaljevic Peles A, Bozina N, Sagud M, Rojnic Kuzman M, Lovric M. MDR1 gene polymorphism: therapeutic response to paroxetine am ong patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 2008;32: 1439-44.
32. Brinar M, Cukovic-Cavka S, Bozina N, Ravic KG, Markos P, Ladic A, et al. MDR1 polymorphisms are associated with inflammatory bowel disease in a cohort of Croatian IBD patients. BMC Gastroenterol 2013;13:57.
33. Basic S, Hajnsek S, Bozina N, Filipcic I, Sporis D, Mislov D, et al. The influence of C3435T polymorphism of ABCB1 gene on penetration of phenobarbital across the blood-brain barrier in patients with generalized epilepsy. Seizure 2008;17: 524-30.
34. Jovanović N, Božina N, Lovrić M, Medved V, Jakovljević M, Peleš AM. The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone. Eur J Clin Pharmacol 2010;66: 1109-17.
35. Luptáková L, Sivaková D, Šrá meková D, Cvíčelová M. The association of cytochrome P450 1B1 Leu432Val polymorphism with biological markers of health and menopausal symptoms in Slovak midlife women. Menopause 2012;19: 216-24.
36. Krivulcik T, Sedlak J, Bartosova Z. Frequency of the three most common polymorphisms in the MDR1 gene in Slovak population. Neoplasma 2009;56: 101-7.
37. Saraeva RB, Paskaleva ID, Doncheva E, Eap CB, Ganev VS. Pharmacogenetics of acenocoumarol: CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5 and ABCB1 gene polymorphisms and dose requirements. J Clin Pharm Ther 2007;32: 641-9.
38. Petrova DT, Yaramov N, Toshev S, Nedeva P, Maslyankov S, von Ahsen N, et al. Genotyping of CYP3A5 polymorphisms among Bulgarian patients with sporadic colorectal cancer and controls. Onkologie 2007;30: 559-63.
39. Petrova DT, Nedeva P, Maslyankov S, Toshev S, Yaramov N, Atanasova S, et al. No association between MDR1 (ABCB1) 2677G >T and 3435C >T polymorphism and sporadic colorectal cancer among Bulgarian patients. J Cancer Res Clin Oncol 2008;134: 317-22.
40. Dolzan V, Rudolf Z, Breskvar K. Human CYP2D6 gene polymorphism in Slovene cancer patients and healthy controls. Carcinogenesis 1995;16: 2675-8.
41. Bohanec Grabar P, Grabnar I, Rozman B, Logar D, Tomsic M, Suput D, et al. Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy- N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis. Drug Metab Dispos 2009;37: 2061-8.
42. Levkovich NN, Gorovenko NG, Myasoedov DV. Association of polymorphic G1934A variant (allele *4) of CYP2D6 gene with increased risk of breast cancer development in Ukrainian women. Exp Oncol 2011;33: 136-9.
43. Semiz S, Dujić T, Ostanek B, Prnjavorac B, Bego T, Malenica M, et al. Analysis of CYP3A4*1B and CYP3A5*3 polymorphisms in population of Bosnia and Herzegovina. Med Glas (Zenica) 2011;8: 84-9.
44. Jaanson P, Marandi T, Kiivet RA, Vasar V, Vään S, Svensson JO, et al. Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype. Psychopharmacology (Berl) 2002;162: 67-73.
45. Sim SC, Kacevska M, Ingelman-Sundberg M. Pharmacogenomics od drug-metabolising enzymes: a recent update on clinical implications and endogenous effects. Pharmacogenomics J 2013;13: 1-11.
46. Turpeinen M, Zanger UM. Cytochrome P450 2B6: function, genetics, and clinical relevance. Drug Metabol Drug Interact 2012;27: 185-97.
47. Mitropoulos K, Johnson L, Vozikis A, Patrinos GP. Relevance of pharmacogenomics for developing countries in Europe. Drug Metabol Drug Interact 2011;26: 143-6.